The concept of Web 3.0 is hot, and Magic Pharma has 5 boards in 5 days

Recently, the concept of Web 3.
0 has continued to be hot and has become a hot topic in the market, and related concept stocks have also received close attention
from investors.
On November 16, Web 3.
0 concept stocks rose sharply again, of which Miracle Pharmaceutical rose in early trading, and the stock has gained 5 days and 5 boards, and its performance is quite active
.
As of the close of trading on November 16, Magic Pharmaceutical's price was 11.
76 yuan, the turnover was 589 million, the turnover rate was 10.
45%, the price-to-earnings (TTM) was 87.
18, and the current total market value was 6.
281 billion
.
According to the data, Miracle Pharmaceutical is a company
engaged in the research and development, production and sales of anti-tumor, cardiovascular and cerebrovascular, cold and cough, pediatric medicine and antifungal drugs.
The company's main products include sodium cantharilate vitamin B6 injection, sodium cantharidate injection, loquat cough granules, strong loquat dew, loquat cough capsules, golden black bone capsules, coral ringworm, jingwu capsules, all-day hemp capsules, Yindanxintai drop pills, etc
.
In recent years, Miratech Pharmaceutical has actively explored OEM brand output, commercial distribution, promoted modern logistics extension services, explored new business models such as third-party logistics business, and invested in the construction of traditional Chinese medicine pieces processing base projects and other health food production cooperation projects, entered the field of large health product production, and continuously lengthened the industrial chain
before and after the company.
On the news, recently, the research team of Professor Fang Bangjiang of Shanghai University of Traditional Chinese Medicine published a paper in the internationally renowned medical journal "Plant Medicine" on the combination of heat and heat (RYN
).
Previously, after winning three consecutive boards, Mirake Pharmaceutical issued an announcement on the evening of November 14 that the company's current production and operation are normal, the main business, external market environment, and industry policies have not undergone major changes, and there is no other material information
that should be disclosed but not disclosed.
At the same time, it is a risk reminder that recently, the company has paid attention to reports related to heat inflammation
compounds.
After verification, the company and its subsidiaries have not obtained the drug production approval number
.
It is reported that the "magic" brand Reyanning granules are products produced and sold by Chongqing Miao Kangzheng Pharmaceutical Co.
, Ltd.
, a subsidiary of Miracle Pharmaceutical; Up to now, the sales revenue of the product during the year is less than 1 million yuan, accounting for no more than 0.
06% of the company's current operating income; The gross profit contribution to the company in the current year is less than 100,000 yuan, accounting for no more than 0.
18% of the company's
net profit in the current period.
The author notes that since November, the company has issued two consecutive announcements
about abnormal fluctuations in stock trading.
On November 1, the company announced that the company's shares have accumulated 20% deviation from the closing price increase for three consecutive trading days (October 27, October 28, October 31, 2022), and the company's stock trading is an abnormal fluctuation
according to the relevant provisions of the listing rules 。 On November 12, the company once again announced that the company's shares have accumulated a deviation of 20% in the closing price increase for three consecutive trading days (November 9, November 10, November 11, 2022), and the company's stock trading is an abnormal volatility according to the relevant provisions of the listing rules
.
According to the third quarter report of 2022, Magic Pharmaceutical's revenue in the first three quarters was 1.
713 billion yuan, a year-on-year increase of 0.
57%; The net profit attributable to the parent was 55.
4457 million yuan, a year-on-year increase of 4.
57%.

Among them, the revenue in the third quarter alone was 511 million yuan, a year-on-year decrease of 6.
73%; The net profit attributable to the parent was 23.
4727 million yuan, a year-on-year increase of 171.
27%.

In addition, pharmaceutical stocks such as Jinhua Shares, Saili Medical, and Huangshan Capsules also closed on the 16th, and many stocks such as Yiqiao Shenzhou and Teyi Pharmaceutical closed up more than 4%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.